Microarray data mining for potential selenium targets in chemoprevention of prostate cancer

Cancer Genomics and Proteomics

Volumn 2, Issue 2, 2005, Pages 97-113

  Zhang, Haitao ^a   Dong, Yan ^a   Zhao, Hongjuan ^b   Brooks, James D ^b   Hawthorn, Lesleyann ^a   Nowak, Norma ^a   Marshall, James R ^a   Gao, Allen C ^a   Ip, Clement ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen receptor; Chemoprevention; Prostate carcinogenesis; Selenium

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BIOLOGICAL MARKER; PROTEIN; PROTEINASE INHIBITOR; RNA; SELENIUM;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CYTOSKELETON; DNA MICROARRAY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; METABOLISM; ONCOGENE; PROSTATE CANCER; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 20344379480     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL and Taylor JR: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276: 1957-1963, 1996.
2. Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S and Rounder J: Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 81: 730-734, 1998.
3. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR and Clark LC: Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 91: 608-612, 2003.
4. Dong Y, Lee SO, Zhang H, Marshall J, Gao AC and Ip C: Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res 64: 19-22, 2004.
5. Dong Y, Zhang H, Hawthorn L, Ganther HE and Ip C: Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Res 63: 52-59, 2003.
6. Zhao H, Whitfield ML, Xu T, Botstein D and Brooks JD: Diverse effects of methylseleninic acid on the transcriptional program of human prostate cancer cells. Mol Biol Cell 15: 506-519, 2004.
7. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR and Sellers WR: Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1: 203-209, 2002.
8. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr and Hampton GM: Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61: 5974-5978, 2001.
9. Lapointe J, Li C, Higgins JP, van de RM, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD and Pollack JR: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101: 811-816, 2004.
10. Jenster G: The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 26: 407-421, 1999.
11. DePrimo SE, Diehn M, Nelson JB, Reiter RE, Matese J, Fero M, Tibshirani R, Brown PO and Brooks JD: Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol 3: RESEARCH0032, 2002.
12. Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L and Lin B: The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 99: 11890-11895, 2002.
13. Kaminski N, Allard JD, Pittet JF, Zuo F, Griffiths MJ, Morris D, Huang X, Sheppard D and Heller RA: Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci USA 97: 1778-1783, 2000.
14. Wang Y, Rea T, Bian J, Gray S and Sun Y: Identification of the genes responsive to etoposide-induced apoptosis: application of DNA chip technology. FEBS Lett 445: 269-273, 1999.
15. Puga A, Xia Y and Elferink C: Role of the aryl hydrocarbon receptor in cell cycle regulation. Chem Biol Interact 141: 117-130, 2002.
16. Ohtsubo M, Kai R, Furuno N, Sekiguchi T, Sekiguchi M, Hayashida H, Kuma K, Miyata T, Fukushige S, Murotsu T et al.: Isolation and characterization of the active cDNA of the human cell cycle gene (RCC1) involved in the regulation of onset of chromosome condensation. Genes Dev 1: 585-593, 1987.
17. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW and Elledge SJ: p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9: 650-662, 1995.
18. Persengiev SP, Devireddy LR and Green MR: Inhibition of apoptosis by ATFx: a novel role for a member of the ATF/CREB family of mammalian bZIP transcription factors. Genes Dev 16: 1806-1814, 2002.
19. Gilley J, Coffer PJ and Ham J: FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 762: 613-622, 2003.
20. Modur V, Nagarajan R, Evers BM and Milbrandt J: FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 277: 47928-47937, 2002.
21. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M and Sellers WR: Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 20: 8969-8982, 2000.
22. Cher ML, Biliran HR Jr, Bhagat S, Meng Y, Che M, Lockett J, Abrams J, Fridman R, Zachareas M and Sheng S: Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci USA 100: 7847-7852, 2003.
23. Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E and Sager R: Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263: 526-529, 1994.
24. Bass R, Fernandez AM and Ellis V: Maspin inhibits cell migration in the absence of protease inhibitory activity. J Biol Chem 277: 46845-46848, 2002.
25. Chen Z, Fan Z, McNeal JE, Nolley R, Caldwell MC, Mahadevappa M, Zhang Z, Warrington JA and Stamey TA: Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer. J Urol 169: 1316-1319, 2003.
26. Lee HK, Driscoll D, Asch H, Asch B and Zhang PJ: Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate 40: 14-19, 1999.
27. Asch HL, Head K, Dong Y, Natoli F, Winston JS, Connolly JL and Asch BB: Widespread loss of gelsolin in breast cancers of humans, mice, and rats. Cancer Res 56: 4841-4845, 1996.
28. Dosaka-Akita H, Hommura F, Fujita H, Kinoshita I, Nishi M, Morikawa T, Katoh H, Kawakami Y and Kuzumaki N: Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res 58: 322-327, 1998.
29. Tanaka M, Mullauer L, Ogiso Y, Fujita H, Moriya S, Furuuchi K, Harabayashi T, Shinohara N, Koyanagi T and Kuzumaki N: Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res 55: 3228-3232, 1995.
30. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A and Mosialos G: CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424: 793-796, 2003.
31. Castro P, Liang H, Liang JC and Nagarajan L: A novel, evolutionarily conserved gene family with putative sequence-specific single-stranded DNA-binding activity. Genomics 80: 78-85, 2002.
32. Semba K, Nishizawa M, Miyajima N, Yoshida MC, Sukegawa J, Yamanashi Y, Sasaki M, Yamamoto T and Toyoshima K: yes-related protooncogene, syn, belongs to the protein-tyrosine kinase family. Proc Natl Acad Sci USA 83: 5459-5463, 1986.
33. Chen D, Guo J, Miki T, Tachibana M and Gahl WA: Molecular cloning of two novel rab genes from human melanocytes. Gene 174: 129-134, 1996.
34. Williams ED and Brooks JD: New molecular approaches for identifying novel targets, mechanisms and biomarkers for prostate cancer chemopreventive agents. Urology 57: 100-102, 2001.
35. Rhodes DR, Barrette TR, Rubin MA, Ghosh D and Chinnaiyan AM: Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 62: 4427-4433, 2002.
36. Luo J, Dunn T, Ewing C, Sauvageot J, Chen Y, Trent J and Isaacs W: Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 51:189-200, 2002.
37. Prakash K, Pirozzi G, Elashoff M, Munger W, Waga I, Dhir R, Kakehi Y and Getzenberg RH: Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci USA 99: 7598-7603, 2002.
38. Kavurma MM and Khachigian LM: Signaling and transcriptional control of Fas ligand gene expression. Cell Death Differ 10: 36-44, 2003.
39. Suhara T, Kim HS, Kirshenbaum LA and Walsh K: Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. Mol Cell Biol 22: 680-691, 2002.
40. Dijkers PF, Medema RH, Lammers JW, Koenderman L and Coffer PJ: Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10: 1201-1204, 2000.
41. Tang TT, Dowbenko D, Jackson A, Toney L, Lewin DA, Dent AL and Lasky LA: The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor. J Biol Chem 277: 14255-14265, 2002.
42. Tang ED, Nunez G, Barr FG and Guan KL: Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 274: 16741-16746, 1999.
43. Guo S, Rena G, Cichy S, He X, Cohen P and Unterman T: Phosphorylation of serine 256 by protein kinase B disrupts transactivation by FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1 promoter activity through a conserved insulin response sequence. J Biol Chem 274: 17184-17192, 1999.
44. Lin J, Adam RM, Santiestevan E and Freeman MR: The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 59: 2891-2897, 1999.
45. Li P, Lee H, Guo S, Unterman TG, Jenster G and Bai W: AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol 23: 104-118, 2003.
46. Jiang C, Wang Z, Ganther H and Lu J: Distinct effects of methylseleninic acid versus selenite on apoptosis, cell cycle, and protein kinase pathways in DU145 human prostate cancer cells. Mol Cancer Ther 1: 1059-1066, 2002.
47. Massague J: TGF-beta signal transduction. Annu Rev Biochem 67: 753-791, 1998.
48. Moses HL, Yang EY and Pietenpol JA: Regulation of epithelial proliferation by TGF-beta. Ciba Found Symp 757: 66-74, 1991.
49. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT and Thompson TC: Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73: 628-635, 1995.
50. Williams RH, Stapleton AM, Yang G, Truong LD, Rogers E, Timme TL, Wheeler TM, Scardino PT and Thompson TC: Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. Clin Cancer Res 2: 635-640, 1996.
51. Kim IY, Ahn HJ, Lang S, Oefelein MG, Oyasu R, Kozlowski JM and Lee C: Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res 4: 1625-1630, 1998.
52. Samatar AA, Wang L, Mirza A, Koseoglu S, Liu S and Kumar CC: Transforming growth factor-beta 2 is a transcriptional target for Akt/protein kinase B via forkhead transcription factor. J Biol Chem 277: 28118-28126, 2002.
53. Chipuk JE, Cornelius SC, Pultz NJ, Jorgensen JS, Bonham MJ, Kim SJ and Danielpour D: The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. J Biol Chem 277: 1240-1248, 2002.